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ABSTRACT 
 Pre-exposure prophylaxis (PrEP) is an effective tool for preventing human 
immunodeficiency virus (HIV) acquisition in sexually active at-risk individuals such as men who 
have sex with men (MSM). The purpose of this study is to examine factors associated with intent 
to engage in risky sexual behavior among HIV-negative college aged (18-24) MSM who are 
currently adherent to PrEP or who have expressed interest in the future adoption of PrEP. A 
multiracial/ethnic sample of 31 men expressing interest in the adoption of PrEP and 6 men 
currently taking PrEP completed a quantitative survey identifying key themes regarding attitudes 
towards PrEP and potential behaviors associated with adherence. Themes associated with current 
adherence to PrEP included protection from HIV infection, the opportunity to engage in sexual 
activities with a non-condom HIV prevention method, and perceived protection from sexually 
transmitted infections. Themes associated with potential adoption of PrEP included protection 
from HIV infection, opportunity to engage in sexual activity with known HIV-positive partners, 
opportunity to engage in sexual activities with a non-condom HIV prevention method, and 
perceived protection from sexually transmitted infections. Review found that decreased condom 
use and increased sexual partners are key themes related to initiation of PrEP, and a decrease in 
frequency of condom use was indicated among the adherent sample. Other key themes identified 
include barriers to PrEP implementation and misinformation regarding sexually transmitted 
infections among the population.  
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INTRODUCTION 
Current evidence supports pre-exposure prophylaxis (PrEP) as an effective means of 
human immunodeficiency virus (HIV) prevention. Though highly successful at protecting 
against HIV, the medication does not provide protection against sexually transmitted infections 
such as syphilis, chlamydia, and gonorrhea. As the use of PrEP continues to rise, so does the 
concern that drug participation occurs simultaneously with increased sexual risk taking within 
already at-risk populations such as young adults, men who have sex with men, and those with 
multiple sexual partners. In 2015 the Centers for Disease Control and Prevention’s Florida State 
Health Profile reported that over 39,000 people in the United States were diagnosed with HIV 
(CDC, 2015). Of these, 4,849 diagnoses occurred within the state of Florida alone. This made 
Florida the 1st among all 50 states in new HIV diagnoses. In the same year, Florida also ranked 
6th in primary and secondary syphilis rates (CDC, 2015). Given the state’s high rankings for 
sexually transmitted diseases, it’s within reason that many Florida persons can be considered at-
risk PrEP candidates and are also at a relatively high risk of sexually transmitted infection (STI) 
acquisition if participating in unprotected intercourse. This study investigated the relationship 
between pre-exposure prophylaxis and sexual decision making in a 18-24-year-old MSM college 
population in Florida. 
Background 
Pre-Exposure Prophylaxis, or PrEP, was introduced as a biomedical intervention for HIV 
contraction in 2012 when the Food and Drug Administration approved daily oral combination 
Tenofovir/Emtricitabine for use in at-risk individuals age eighteen and older as a means of HIV 
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prevention (Weinstein, Yang, & Cohen, 2017). In 2014, the CDC endorsed the use of PrEP, 
introducing clinical guidelines and recommendations for the drug, which were then revised in 
2017 (US Public Health Service, 2018). Throughout its history, the drug has proven to be a 
valuable asset in preventing new HIV infections, reducing the risk of HIV acquisition via 
intercourse by over 90% in adherent patients (McCormack et al., 2016). Despite some degree of 
stigma and social pushback regarding the use of PrEP, the drug has become largely accepted 
amongst men who have sex with men (MSM) as a means of providing confidence in sexual 
safety to those such as with multiple sexual partners or in serodiscordant relationships 
(relationships in which only one partner is living with HIV) (Hoornenborg et al., 2017).  
Prevalence of Risky Sexual Behavior 
Despite the success that PrEP has shown in preventing acquisition when strictly adhering 
to the prophylaxis regime, concerns have arisen regarding potential consequences of the drug’s 
expansion amongst at-risk populations (Alaei, Paynter, Juan & Alaei, 2016). Though the clinical 
guidelines for PrEP outline the use of prophylaxis concomitantly with condoms rather than as a 
replacement (CDC, 2018), concern remains that PrEP may inadvertently promote increased 
sexual risk taking in the form of decreased condom use (Alaei et al., 2016). One study performed 
in Los Angeles investigating the potential adoption of PrEP among HIV negative queer men 
in serodiscordant relationships found that 64% of participants would be likely to increase sexual 
risk behaviors, and 60% of participants indicated that they were likely to decrease or discontinue 
the use of condoms (Brooks et al., 2012). Similarly, a longitudinal study conducted in Rhode 
Island followed patients initiating PrEP, collecting data at 3- and 6-months following initiation of 
treatment (Oldenburg et al., 2018). Results showed that though there was no significant change 
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in number of sexual partners, participants displayed a significant increase in condomless anal sex 
at six months as compared to the baseline. These results indicate that individuals actively 
participating in PrEP therapy may attain a heightened perception of sexual 
protection, consequently decreasing their use of condoms as they grow more at ease. This 
information is of particular concern when considering that those at substantial risk for HIV, such 
as those with a significantly high number of sexual partners or inconsistent condom use, are 
often the same patients that more readily increase risk behaviors and abandon condoms once on 
PrEP (Traeger et al., 2018). 
Prevalence of Sexually Transmitted Infections (STIs) 
The CDC reports that MSM are at relatively high risk for sexually transmitted 
infections, specifically primary and secondary syphilis and antimicrobial-resistant gonorrhea, 
when compared to both men and women who have sex with women only (2018). This becomes 
of greater concern when considering the current upward trends in STI proliferation, such as how 
the rate of syphilis acquisition amongst men has increased by 70% over the past 5 years - 58% of 
these cases occurring among MSM (Montaño et al., 2019). Further, the CDC also reports that 
youth aged 15-24 years account for half of all new STI diagnoses (2018). While this increasing 
rate of STIs was present prior to the adoption of PrEP, it’s important to consider that 
compensatory sexual risk behavior as a result of PrEP may certainly be exacerbating an already 
present and growing issue within the United States while challenging ongoing prevention 
methods. In a study conducted on patients that began to take PrEP at the Kaiser Permanente 
Northern California health systems, 42% were diagnosed with either gonorrhea, syphilis, or 
chlamydia during their first year of PrEP use (Marcus, Katz, Krakower, & Calabrese, 2019). 
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While the authors of this study concede that these numbers may be attributed to increased STI 
testing amongst PrEP users as a result of the regular checkups outlined by PrEP clinical 
guidelines, one must consider that prophylaxis does not protect against such STIs, and the 
populations at greatest risk for STIs are potentially diminishing condom use as a result of 
HIV protection (Marcus et al., 2019).  
PrEP for College Aged Young Adults 
The CDC reports that in 2017 youth aged 13 to 24 made up 21% of the 38,739 new HIV 
diagnoses that year (2019). Within this age group, 79% of the new diagnoses belonged to young 
adults age 20-24 (CDC, 2019).  These numbers serve as a strong indicator that many college-age 
(18-24 years of age) students fall within the at-risk classification to be considered for PrEP. 
Concordantly, in January 2019 the American College Health Association released new 
guidelines for providing PrEP in college health centers, further expanding PrEP’s already 
growing reach on college campuses.  
In addition to being at-risk for HIV, it is also suggested that this age group is at the 
highest risk of practicing riskier sexual behavior once initiating PrEP treatment. A 2014 study 
was performed in the United States with the purpose of assessing the sexual risk trajectories of 
MSM with PrEP delivery (Pines et. al., 2014). The results of this study were classified into three 
groups, identified as low-risk, moderate-risk, and high-risk. Results showed that in comparison, 
high-risk classification was associated with younger age (along with Caucasian race, having 
symptoms of distress or depression, and substance abuse) (Pines et. al., 2014). As PrEP outreach 
to college students continues to expand, one must deliberate how such implementation may 
affect this population’s overall sexual health outside the scope of HIV.  
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Significance 
College students that belong to the MSM community have been demonstrated to have 
high candidacy for PrEP use, high projected risk of increased sexual risk-taking following PrEP 
initiation, and increased risk for sexually transmitted infections. Given this knowledge, it’s 
important that the comprehensive sexual health of 18-24 year old MSM at-risk for HIV is not 
neglected as the United States continues to roll out PrEP as an intervention for HIV. In 
accordance with PrEP’s clinical guidelines, regular screenings are recommended to assess for 
alterations in patient’s HIV status or renal function (US Public Health Service, 2018).  In 
addition to being beneficial for early detection and treatment of STIs, these visits provide an 
ideal time for nurses to discuss sexual health, promote condom use, and establish ongoing 
relationships with college PrEP users. Focusing on the behavioral impact of PrEP aims to 
investigate whether a population limited to college students will present with similar increases in 
sexual risk behavior as those performed on larger MSM populations, as well as to explore 
college participant’s attitudes towards PrEP’s influence. This may in turn allow university 
healthcare providers to better identify and treat patients at-risk for sexually transmitted 
infections, and to better anticipate barriers in implementing PrEP amongst young adults.  
Review of Current Literature.  
At this time, there is limited literature regarding sexual risk behavior intentions related to 
PrEP use in a college population. Studies have been performed in the past exploring the potential 
for future adoption of PrEP and anticipated risk behaviors (Brooks et. al., 2012; Grov, Whitfield, 
Rendina, Ventuneac & Parsons, 2015). However, these studies strictly investigated potential 
behaviors, and did not assess actual modifications in sexual behavior when presented with the 
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real-world opportunity after initiating PrEP – these studies also did not investigate a specific age 
group. A similar study to this exploring motivation for reducing other HIV risk-reduction 
practices was completed in Kenya and South Africa (Corneli et. al., 2015); however, this study 
strictly collected data from women, and responses were influenced by such concerns as having 
sex in exchange for material goods and minimizing relationship conflicts.  
The current leading systematic review concerning PrEP’s implications for risk behavior 
in MSM identifies that no studies to date have included questions regarding the participant’s use 
of condoms prior to PrEP initiation, a key factor in identifying whether current risk behavior can 
actually be associated to PrEP use (Freeborn & Portillo, 2018). Other landmark studies 
performed included double-blind placebo trials, in which participants were unaware of whether 
they were truly receiving protection from HIV (Grant et. al., 2010; Liu et. al., 2013). The results 
from these studies cannot be applied to gauging the intervention’s true impact, given that patient 
behavior is hypothesized to be contingent upon medication adherence and confidence in the 
medication as a protective measure against HIV. If participants are unsure whether they are truly 
receiving prophylaxis, they may be less likely to display increased sexual freedom for fear of not 
being protected from HIV acquisition. This study aims to address these gaps in the literature, 
investigating participant’s own attitudes towards PrEP’s influence. 
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METHODOLOGY 
Study Design and Instrument 
A cross-sectional study design was utilized to identify the association of PrEP use and 
sexual risk behavior intentions. Through convenience sampling, college age MSM were invited 
to participate in an original online questionnaire to identify if PrEP use is associated with actual 
or anticipated changes in sexual risk behavior. The survey asked various questions related to 
sexual behavior and perceived behaviors, including: 
 Demographic information 
 Current PrEP status 
 Frequency of condom use 
 Motives for initiating PrEP 
 Attitudes towards engaging in intercourse with HIV positive partners 
Human Subjects 
 Approval was obtained from the Institutional Review Board (IRB) at the University of 
Central Florida (Appendix C). The survey did not request nor collect any identifying 
information. Participants were eligible to withdraw from the study at any time without fear of 
penalty, and there were minimal risks (i.e. anxiety related to sensitive questions) associated with 
the study. Inclusion criteria determines that participants must be 18-24 years of age, identify as a 
male that has sex with men, are cognitively able to perform mobile device operations, and either 
be currently adherent to PrEP or show interest in beginning PrEP. Exclusion criteria includes 
persons unaware of PrEP prior to the survey, under the age of 18 or above the age of 24, non-
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English speaking, unable to operate a mobile device, identify as female, or do not engage in 
sexual activity with men.  
Sample and Setting 
 Initial protocol approval included a 2019 Orlando Pride event and flyers to be posted at 
university health clinics (Appendix D) as recruitment sources. Later modifications submitted for 
approval expanded recruitment sites to include a 2019 Gainesville Pride event, additional sexual 
wellness clinics, and online flyer postings through Facebook®. A convenience sample was used 
for this study, utilizing street-intercept at LGBTQ pride events by means of approaching age-
appropriate individuals with a survey flyer and mobile tablet. Prior works, such as a study 
conducted in New York City exploring insurance-related barriers to accessing dental care, have 
identified street-intercept as a cost-effective method for sampling a geographically defined 
population while reducing the biases introduced by self-referral (Schrimshaw et al., 2011). 
Another study exploring the PrEP continuum of care was performed at Miami Gay Pride in 2018, 
and established venue intercept as an effective means of recruiting MSM for anonymous PrEP-
related data collection (Algarin et al., 2019).  
Surveys were administered by the primary investigator, who approached potential 
participants with a printed flyer detailing the study and an iPad that could be used to begin the 
survey. The investigator explained his role at the university and the objectives of the study, and 
further explained approximate survey completion time and the gift card incentive being offered 
upon survey completion. Many of the individuals approached opted to scan the flyer’s QR code 
with their mobile device to load the Qualtrics® site and complete the survey on their own device 
at a later time, though some opted to utilize the provided iPad to complete the survey on site.  
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Additional recruitment was achieved through posting recruitment flyers in the lobbies of 
the University of Central Florida’s Student Health Services, Bliss Healthcare, and the University 
of Central Florida’s Recreation and Wellness Center’s sexually transmitted disease testing 
center. These flyers included QR codes that could be scanned with the camera app of a mobile 
device, which would then open the survey on their device’s primary browser. 
Procedures 
 Permission was obtained from each healthcare location to provide recruitment flyers to be 
advertised in their lobby areas pending IRB approval. The survey was developed using 
Qualtrics® electronic software, and upon completion of the original survey participants were 
redirected to a secondary Qualtrics® survey on which they could input a valid email address for 
the purpose of incentive distribution. Each participant would receive a $5 digital gift card to 
Amazon.com, and the use of a secondary Qualtrics® survey ensured dissociation of responses 
from email addresses. This method also prevented duplication of responses for the purpose of 
claiming multiple incentives by requiring access-by-invitation and prohibiting multiple sessions. 
All data was collected using an electronic survey - no printed distributions were utilized. The 
survey was kept live for approximately three months, from October 2019 to December 2019. 
 The initial section of the data-collection survey utilized a branch-style logic, sending 
respondents through different survey paths dependent upon their responses to key eligibility 
questions. All attempted participants that did not meet key inclusion criteria (male gender, 
identify as MSM, age 18-24) were automatically sent to survey completion on the basis of 
screening failure and thanked for their interest. Utilizing browser cookies, these participants were 
prohibited from re-accessing the survey in order to prevent them from answering differently in 
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an attempt to participate and claim survey incentives. Likewise, those that expressed no interest 
in the adoption of PrEP or those who had not heard of PrEP prior to survey initiation were also 
sent to survey completion. Those that met eligibility criteria and progressed to the next section of 
the survey were asked the second branching question pertaining to PrEP status. Those that 
identified as currently taking PrEP were sent down survey branch A, exploring history of PrEP 
use and current attitudes and sexual behavior (Appendix A). Those that identified as expressing 
interest in the adoption of PrEP received survey branch B, exploring rationale for interest in 
PrEP and anticipated behaviors should PrEP be adopted (Appendix B).  
Measurements 
 The measures used in this study consisted of demographic information, Likert scale 
questions, and the option for free-text “other” responses if the provided multiple choices did not 
fully reflect participant attitudes. Survey questions were adapted from those of a previous study 
on a similar topic performed by doctoral candidate Angel Algarin at Florida International 
University (Algarin et al., 2019), and the adapted survey was reviewed by Angel given his 
expertise in venue intercept. Demographic data collected included such information as gender 
identity, sexual orientation, and race and ethnicity. Correlation between these attributes 
(including relationship status and preferred sexual position) and risk behavior were explored, 
though the sample size was too limited to make meaningful comparisons between groups. Likert 
scale questions investigated participant attitudes towards such concepts as PrEP education, 
frequency of condom use, and HIV exposure. In this scale, 1 was strongly agree, 2 was agree, 3 
was somewhat agree, 4 was somewhat disagree, 5 was disagree, and 6 indicated strongly 
disagree 
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Data Analysis 
 Using the data generated from Qualtrics® descriptive statistics including means and 
proportions were calculated to describe characteristics of the sample and explain the data. 
Responses in which participants utilized the free-text “other” option were discussed separately, 
coded into existing options, or categorized and coded into numerical values in order to be 
quantitatively analyzed. 
RESULTS 
Demographic Data 
 A total of 31 men expressing interest in the adoption of PrEP and 6  men currently taking 
PrEP participated in the study (see Appendix E). The sample included White (n=14), Black or 
African American (n=9), American Indian or Alaskan Native (n=1), Asian or Pacific Islander 
(n=2), Multiracial (n=4), undisclosed race (n=7), and Hispanic or Latino (n=12) participants. The 
sample included cisgender males (n=29) as well as transgender males (n=2) and those who chose 
not to disclose (n=6). Included in the sample were those that identify as gay (n=21), bisexual 
(n=8), and pansexual (n=2). Some participants (n=6) chose not to disclose sexual orientation 
beyond MSM.  The mean age of all participants was 21, with an age range of 19 to 24 years. 
Most participants identified as single (n=20), whereas (n=11) identified as in a relationship and 
(n=6) preferred not to say. Of those in a relationship, half (n=3) considered their relationship to 
be “open”. The sample included men whose preferred sexual positions included “top” (anal 
insertive) (n=13), “bottom” (anal receptive)(n=8), versatile (anal insertive or receptive)(n=10), 
and those who preferred not to disclose (n=6). 
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Primary Motivators for Initiating PrEP 
 In the survey participants expressing an interest in initiating PrEP were asked to identify 
their primary motivations for seeking treatment. Primary reported motivations included having 
sexual intercourse with decreased fear of HIV contraction (n=20; 65% of respondents), ability to 
have sex without condoms with decreased anxiety (n=15; 48%) and having current sexual 
partner(s) who are currently HIV positive (n=7; 23%). In the same question 42% (n=13) of 
participants identified reduced risk of sexually transmitted infections when having intercourse as 
a motivation for initiating PrEP (see Appendix F).  
 Participants currently taking PrEP identified their primary reason for initiating treatment 
as being able to have sex without worrying about HIV as much, with all responding participants 
(n=4; 100%) indicating this as their number one reason. Being able to use condoms less when 
having sex was identified as the second greatest influence for initiating PrEP, with 75% (n=3) of 
participants identifying this as their second most influential factor in beginning treatment. The 
remaining participants (n=1; 25%) indicated that this was their third motivation for initiating 
treatment. The final motivation for initiating PrEP identified was ability to engage in sexual 
activity without fear of sexually transmitted infections, with 67% (n=2) of participants 
identifying this as their third most influential factor and the remaining (n=1; 33%) identifying 
this as their second most influential factor (see Appendix F). 
Sexual Risk Behaviors 
Participants expressing an interest in PrEP were asked about sexual risk behaviors 
hypothesized to be associated with PrEP use (such as decreased frequency of condom use and 
increased number of sexual partners) using a Likert scale. Almost all (n=22; 95.7%) of 
16 
 
responding participants agreed that they would be more protected against HIV if they started 
taking PrEP, with 4.35% (n=1) somewhat disagreeing. In a separate question, 100% (n=23) of 
responding participants agreed that they would feel safer having sex with a new sexual partner 
knowing that there is a possibility the partner may be taking PrEP. When asked about whether 
they would stop using condoms after beginning PrEP, 70% (n=16) of participants disagreed. The 
remaining 30% (n=7) agreed that they would discontinue condom use, with 9% (n=2) strongly 
agreeing, 13% (n=3) agreeing, and 9% (n=2) somewhat agreeing. When questioned regarding 
their attitude towards intercourse with HIV positive individuals, 78% (n=18) of participants 
agreed that they would feel comfortable having sex with someone that is HIV positive if they 
themselves were on PrEP and using a condom. Responses were nearly split even when 
participants were asked whether they anticipated a greater number of sexual partners after 
initiating PrEP, with 52% (n=12) agreeing and 48% (n=11) disagreeing that their partner count 
would increase. When asked about whether they would prefer to have sex without condoms 
though it would increase STI risk, 35% (n=3) of the non-adherent sample indicated that they 
would prefer to abandon condoms in lieu of STI protection. 
Participants currently taking PrEP were asked to complete similar Likert-style questions, 
investigating their attitudes toward their current risk activities and association with PrEP. Of 
these participants, 100% (n=6) reported that being on PrEP makes them feel more protected 
against HIV than if they were not on PrEP, and all participants (n=6; 100%) also reported that 
they feel safer having sex with new partners knowing that they may also be taking PrEP. When 
questioned regarding condom use, all participants (n=6; 100%) disagreed with the statement that 
they do not need to use condoms while on PrEP. When questioned regarding provider education 
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50% (n=3) of participants agreed that their provider emphasized the importance of continuing 
condom use while taking PrEP, with the remaining participants (n=3; 50%) disagreeing that their 
provider educated them. Further, 75% (n=3) of responding participants agreed that their provider 
educated them regarding the risks of sexually transmitted infections while on PrEP. 
Barriers to Implementation  
Those interested in the adoption of PrEP were asked a key question related to current 
barriers of implementation. The primary reported barrier to implementation was found to be the 
financial burden, with 33.3% (n=12) of participants reporting that the drug is too expensive 
and/or their insurance does not cover the medication. Other reported barriers included lack of a 
provider from which one could obtain a PrEP prescription (n=6; 16.7%), concerns regarding the 
side effects of the drug (n=6; 16.7%), being uninterested in taking a daily pill or fearful of 
forgetting a daily pill (n=6; 16.7%), and being unwilling or unable to visit a provider every 3 
months for follow-up (n=2; 5.6%). Remaining participants (n=4; 11.1%) opted to use the free-
text “other” option to identify their primary barrier(s) to PrEP, and identified the following: 1) 
lacking information about the pill and not knowing who to ask, 2) perceiving that they have not 
yet come into contact with someone who is HIV positive, 3) being on their parent’s insurance 
and not yet being “out” as LGBTQ, and 4) having not yet been motivated enough to call their 
primary care provider to discuss the medication. 
Frequency of Condom Use 
Adherent participants were asked to describe their current rate of condom use. Half of 
participants (n=3; 50%) indicated that they always use condoms. Some participants (n=2; 33.3%) 
indicated that they usually use condoms, and the remaining (n=1; 16.7%) indicated that they 
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rarely use condoms. Participants were asked a similar question describing their condom use prior 
to initiating PrEP, in which 60% (n=3) of respondents identified that they always used condoms, 
and the remaining 40% (n=2) identified that they usually used condoms. When asked about 
whether they would prefer to have sex without condoms though it would increase STI risk, 75% 
(n=3) of the adherent sample indicated that they would prefer to abandon condoms in lieu of STI 
protection. 
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DISCUSSION 
In this sample of 31 men expressing interest in the adoption of PrEP and 6 men currently 
taking PrEP it is found that the primary motivations for initiating PrEP treatment include reduced 
fear of HIV when engaging in sexual activity, increased opportunity to decrease condom use 
with less anxiety, increased opportunity to engage in sexual activity with partners living with 
HIV, and reduced anxiety related to sexually transmitted infections when engaging in sexual 
activity. Data shows that the collegiate MSM community feels more protected against HIV when 
taking PrEP, and feel increased comfort in engaging with new sexual partners knowing there is a 
possibility that they may be taking PrEP. However, attitudes related to engaging in sexual 
activity with HIV positive individuals and an increased number of sexual partners were less 
consistent.  Data shows that the primary barrier to PrEP implementation among interested 
college-age MSM is the cost of the drug and/or lack of insurance coverage to offset costs. 
Additional barriers included lack of a reliable provider, concerns regarding adverse effects, and 
lack of interest in the daily pill requirement. Barriers to implementation among the currently 
adherent sample were identified as lack of education from the provider related to condom use 
and sexually transmitted infection transmissions when taking PrEP. 
Protection against sexually transmitted infections appears to be a common 
misconception, as both participants interested in PrEP and those currently adherent identified 
protection as a benefit of PrEP. Misunderstanding may exist regarding the intended use and 
limitations of PrEP, as college aged MSM may possess false interpretation of the drug’s true 
mechanisms and scope. Moreover, this indicates the potential of a general misunderstanding 
regarding the nature of various sexually transmitted infections among college aged MSM in that 
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there may be a lack of knowledge pertaining to the differences between sexually transmitted 
diseases such as those of viral, bacterial and parasitic nature. In the recent study performed in 
Northern California exploring STI rates among newly adherent PrEP users, results found that 
42% of patients were diagnosed with an STI during their first year of PrEP use (Marcus et al., 
2019). The data collected in this study provides explanation for such results, indicating that lack 
of knowledge may place PrEP users at increased risk for sexually transmitted infections. Another 
possible explanation for the results of the 2019 study is conscious disregard for sexually 
transmitted infections in favor of unprotected intercourse. Data from this study identified that 
41% of the sample would prefer to have sex without condoms in lieu of decreased STI risk, 
indicating that apathy towards STIs (perhaps due to their curable nature when compared to HIV) 
may be as significant a risk as lack of information. This information supports concerns of rising 
STI rates in recent years among the MSM community (Montaño et al., 2019), and indicates that 
the college MSM population remains at proportionately high risk as PrEP use expands across 
college campuses. 
Though nearly all participants identified decreased fear of HIV during sexual activity as a 
motivation for taking PrEP, some non-adherent participants expressed that they would not feel 
comfortable having sex with someone that is known HIV positive while taking PrEP and using a 
condom. Further exploration would be necessary to determine whether these participants would 
willingly engage in sexual activity with an HIV positive individual under the aforementioned 
circumstances (though with compromised comfort levels), or if this data may be interpreted that 
the remaining participants would not willingly engage in sexual activity with a known HIV 
positive individual at all. Should the latter be indicated, this brings in to question primary 
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motivations for taking PrEP – if one would not voluntarily engage with an HIV positive 
individual, and is not at risk for other transmission methods such as injection drug use, one 
would feasibly have no reason for taking daily prophylaxis. This indicates that distrust of sexual 
partners may also be influential in college aged MSM’s decisions to take PrEP, in that some 
sexually active men may doubt their partner’s status or willingness to disclose true status. This 
may also indicate a distrust in the efficacy of the drug, in that participants perceive significant 
continued risk of transmission despite adherence.  
Regarding condom use, only half of participants currently taking PrEP indicated that their 
provider emphasized continued condom use while taking PrEP, and 25% indicated that their 
provider failed to provide adequate education regarding STI risk while taking PrEP and engaging 
in sexual activity. When asked about condom use prior to initiating PrEP treatment, 60% of 
currently adherent participants reported that they always used condoms, and the remaining 40% 
identified that they usually used condoms. In contrast, when asked about current condom use 
(subsequent to initiating PrEP) only 40% of respondents indicated that they always use condoms 
while 40% indicated that they usually use condoms and the remaining 20% indicated that they 
rarely use condoms. This information should be considered along with data collected from the 
non-adherent sample in which 30% (n=7) indicated that they expected a discontinue in condom 
use after they initiate PrEP. When comparing these results to the study performed in Los Angeles 
investigating the potential adoption of PrEP among a broader sample, in which 60% of 
participants indicated that they would likely decrease condom use (Brooks et al., 2012), it is 
suggested that the college population may be less willing to abandon condom use as compared to 
the general MSM population. However, the indicated margin of decrease does still suggest an 
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association between PrEP adherence and decreased condom use, though not to as great of an 
extent. Given this difference, future research drawing comparisons among age groups may help 
clarify why the college sample was less likely to decrease condom use once beginning PrEP. 
When surveying participants interested in PrEP but not currently adherent, the sample 
was asked to disclose their rationale for not having initiated treatment yet. The most common 
reasoning was cost of drug and/or lack of insurance coverage, with 33% of interested participants 
identifying this as their primary barrier. Other primary factors identified included lack of a 
reliable provider from which one could receive a prescription (16%), being uninterested in taking 
a daily pill or fear of forgetting daily doses (16%), and fear of drug side effects (16%). These 
barriers correspond with prior studies exploring the greater MSM population, in which key 
themes related to healthcare systems included lack of provider communication and awareness 
about PrEP, lack of access, and most consistently lack of funding (Pinto et al., 2018). These 
findings also correspond with barriers identified on an individual patient level, including 
concerns related to potential side effects, unwillingness to engage with primary care providers 
about PrEP, and lack of financial resources. Given that findings align when limited strictly to a 
college population, it is indicated that universities must continue to work with healthcare systems 
in prioritizing PrEP education and funding while taking into consideration unique barriers such 
as stigma surrounding sexuality and HIV while remaining dependent on parents. 
Limitations 
The results of this study are unable to be generalized to all college age MSM due to the 
limited number of participants within the sample. Additionally, all participants were recruited 
from a similar geographic area. Recruiting a larger sample size utilizing the same specific 
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inclusion criteria across various geographic areas (i.e. multiple university campuses/cities) would 
be better able to yield more conclusive results.  
Throughout data collection having specific inclusion criteria was identified as the most 
significant barrier to recruitment via street-intercept. Due to the specific age, gender, and sexual 
orientation requirements of the survey, in addition to requiring PrEP adherence or interest in 
adherence, engaging applicable participants through randomized street intercept posed to be 
difficult in spite of being conducted at a Pride event. Approached individuals may have met 
some of the criteria, but often did not meet all. Because of this limitation recruitment was 
expanded to include additional sites (i.e. Facebook, Student Health Services) to increase survey 
reach and allow participants to initiate recruitment once they had reviewed inclusion criteria on 
the flyer and self-determined eligibility. In order to protect the privacy of Orlando Pride 
attendees the on-site recruiter did not ask participants whether they met inclusion criteria, though 
they were provided a description of the survey and flyer to review. As a result, a greater portion 
of individuals initiating the survey experienced screening failure than those recruited via posted 
flyers. Recruitment was further limited by the primary investigator being the sole recruiter 
present at the Pride events. Utilizing a team-based approach to recruitment would highly benefit 
intercept-style recruitment as demonstrated by past studies (Algarin et al., 2019) as it would 
allow for multiple participants to take the survey simultaneously on multiple devices and further 
increase the reach of recruitment at the venue.   
Due to the sensitive nature of the study’s topic and survey questions, participants were 
not forced to respond to any questions other than those used to determine eligibility status. This 
was done in order to minimize participant discomfort and prevent occurrences of participants 
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withdrawing from the survey early in lieu of answering any specific question(s). As a result of 
this there were inconsistencies in response rates on a question-by-question basis, complicating 
quantitative data analysis. Future studies with may benefit from forcing responses for survey 
progression, particularly for questions that are key to study subject. It is also hypothesized that 
providing an incentive may have influenced response rates, as some participants may choose to 
skip more lengthy/complicated questions in favor of speedier incentive distribution and/or 
returning to venue activities.  
Given the self-report nature of the survey, some results may be skewed in that 
participants are susceptible to a pressure to respond with what may be perceived as the “correct” 
answer rather than the most accurate answer. Minimization of this effect was attempted through 
anonymous data collection and careful wording of survey questions. However, given the 
sensitive nature of some questions it remains possible that participants may have experienced 
response bias in which they felt compelled to select the answer they deemed more socially 
acceptable.  
Recommendations for Education and Practice 
This survey indicated that college age MSM may demonstrate increase in risk behavior 
(such as a decrease in frequency of condom use) after initiating PrEP treatment. Primary care 
providers and nurses for college-aged MSM may use this insight to aid in assessment of patient 
intent. While behaviors such as increased number of sexual should be discussed openly and 
without judgement, education regarding overall sexual wellness and risk factors for other 
sexually transmitted should be provided by healthcare professionals serving college men 
interested in PrEP. Specifically, patient education regarding the outstanding risk other sexually 
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transmitted diseases such as Syphilis, Chlamydia, Gonorrhea, Hepatitis C, HPV, and 
Trichomoniasis should be provided. Such knowledge may allow adherent patients to make more 
educated decisions regarding condom use, considering risk factors other than that of HIV. 
Further, the study identified significant gaps in population education regarding sexually 
transmitted infections in relation to PrEP. It is advisable that healthcare providers place an 
emphasis on sexually transmitted infections when providing PrEP education, identifying the 
symptoms associated with commonly seen STIs among the population (i.e. syphilis, gonorrhea) 
and treatments associated with such infections in order to promote early detection and treatment 
in an at-risk population. Given that the use of barrier methods within the population may be 
negatively impacted by PrEP, early detection and treatment is essential in the prevention of 
transmission. 
The study additionally identified common barriers to PrEP implementation among the 
population, including lack of providers offering the service and concerns regarding affordability 
or insurance options. It is advisable that providers ask patients they believe to be at-risk whether 
they have heard of or considered PrEP, and that they aid in exploring coverage options or local 
community resources in order to minimize barriers to care. 
Recommendations for Future Research 
Future research should further explore intent to engage in sexual risk behavior associated 
with PrEP use on a larger scale. Further longitudinal studies could also investigate the use of 
PrEP on a continuum, assessing initial intent along with actual observed behaviors throughout 
the course of treatment. Future research may also further explore misconceptions among college-
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age MSM regarding sexually transmitted infections, and attitudes towards STIs related to PrEP. 
Whether PrEP use is associated with an increased number of sexually transmitted infections in a 
college population could also be investigated. 
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APPENDIX A: DATA COLLECTION INSTRUMENT 
(PARTICIPANTS CURRENTLY TAKING PREP) 
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Start of Block: Eligibility Criteria 
Q2 I am within 18-24 years of age. 
 True  (1)  
 False  (2)  
 
Q3 I identify as male, and I engage in sexual activity with other men. 
 True  (1)  
 False  (2)  
 
Q4 Which of the following describes your current Pre-Exposure Prophylaxis (PrEP, or Truvada®) status? 
I am currently taking daily PrEP.  (1)  
 I am not currently taking PrEP, but I may be interested in beginning PrEP treatment in the future.  
(2)  
 I am not currently taking PrEP, and I do not intend to ever start taking PrEP.  (3)  
 I do not know what PrEP is -or- I had not heard of PrEP prior to this survey.  (4)  
 
End of Block: Eligibility Criteria 
 
Start of Block: Demographic Information 
 
Q5 What is your race? 
 American Indian or Alaskan Native  (1)  
 Asian of Pacific Islander  (2)  
 Black or African American  (3)  
 Multiracial  (4)  
 White  (5)  
 Other  (6)  
Display This Question: 
If What is your race? = Other 
Q55 Please specify race: 
________________________________________________________________ 
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Q6 Are you Hispanic or Latino? 
 Yes  (1)  
 No  (2)  
 
Q7 What is your age? 
▼ 18 (8) ... 24 (14) 
 
Q8 Which of the following best describes your current gender? 
 Male (1)  
 Transgender (Female to Male)  (2)  
 Other (3)  
Display This Question: 
If Which of the following best describes your current gender? = Other 
Q57 Please specify gender: 
________________________________________________________________ 
 
Q9 Which of the following best describes your sexual orientation? 
 Gay  (1)  
 Bisexual  (2)  
 Pansexual  (3)  
 Other  (4)  
Display This Question: 
If Which of the following best describes your sexual orientation? = Other 
Q58 Please specify sexual orientation: 
________________________________________________________________ 
 
Q13 What is your current relationship status? 
 Single (Never Married)  (1)  
 Single (Divorced)  (2) 
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 In a Relationship (Exclusive)  (3)  
 In a Relationship (Open Relationship or Open to Group Intercourse)  (4)  
 Married (Exclusive)  (5)  
 Married (Open Relationship or Open to Group Intercourse)  (6)  
 
Q14 Which of the following best describes your preferred anal sex position? 
 Strictly Top  (1)  
 Versatile Top  (2)  
 Versatile  (3)  
 Versatile Bottom  (4)  
 Strictly Bottom  (5)  
 
Q10 What is your highest education received? 
▼ Current College Student (Undergraduate or Graduate Student) (1) ... Graduate Level Degree (10) 
 
Q12 Which of the following describes your current Pre-Exposure Prophylaxis (PrEP, or Truvada®) status? 
 I am currently taking daily PrEP.  (1)  
 I am not currently taking PrEP, but I may be interested in beginning PrEP treatment in the future.  
(2)  
 
End of Block: Demographic Information 
Start of Block: Participants Currently Taking PrEP 
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Q12 How long have you been taking PrEP, in months? (e.g. taking PrEP daily uninterrupted?) 
 0-3 Months  (1)  
 4-6 Months  (2)  
 7-9 Months  (3)  
 10-12 Months  (4)  
 Longer Than One Year  (5)  
 
Q15 Please rank your top reasons for taking PrEP (e.g. reason for seeking PrEP prescription). Rank as 
many as apply, with the primary reason(s) placed at the top of the box in order of significance (top to 
bottom). If none apply, place all items in the N/A box. 
 
 
Select responses by dragging the options from the left to the appropriate box to the right. 
Please rank top (most impactful) to bottom (least 
impactful) N/A - This reason did not influence my decision. 
______ I am able to hax sex without worrying about 
HIV as much. (1) 
______ I am able to hax sex without worrying about 
HIV as much. (1) 
______ I am able to take drugs using needles without 
worrying about HIV as much. (2) 
______ I am able to take drugs using needles without 
worrying about HIV as much. (2) 
______ I am able to use condoms less when having 
sex. (3) 
______ I am able to use condoms less when having 
sex. (3) 
______ One or more of my sexual partners is HIV 
positive. (4) 
______ One or more of my sexual partners is HIV 
positive. (4) 
______ I am able to have sex without worrying about 
sexually transmitted infections as much. (5) 
______ I am able to have sex without worrying about 
sexually transmitted infections as much. (5) 
______ Other (Specify Below) (6) ______ Other (Specify Below) (6) 
Display This Question: 
If Please rank your top reasons for taking PrEP (e.g. reason for seeking PrEP prescription). Rank as... = Other 
(Specify Below) [ Please rank top (most impactful) to bottom (least impactful) ] 
Q59 Please specify other reason for taking PrEP: 
________________________________________________________________ 
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Q16 Which of the following best describes your current rate of condom use? 
 I always use condoms  (1)  
 I usually use condoms  (2)  
 I rarely use condoms  (3)  
 I never use condoms  (4)  
 
Q17 Which of the following best describes your condom use before PrEP? 
 I always used condoms  (1)  
 I usually used condoms  (2)  
 I rarely used condoms  (3)  
 I never used condoms  (4)  
 
Q18 How have your condom use patterns changed since beginning PrEP? 
 I now use condoms much more frequently  (1)  
 I now use condoms somewhat more frequently  (2)  
 My condom use has not changed since beginning PrEP  (3)  
 I now use condoms somewhat less frequently  (4)  
 I now use condoms much less frequently  (5)  
 
Q19 How many male anal sex partners have you had in the past six months? 
▼ 0 (9) ... 26+ (7) 
 
Q20 In the past 6 months, how many times have you had group intercourse involving anal sex in which 
3 or more men participated (including yourself)? (If you have been taking PrEP for less than 6 months, 
please only include group intercourse that took place while on PrEP). (If you have not had group 
intercourse, select 0) 
▼ 0 (1) ... 11+ (12) 
 
Skip To: Q23 If In the past 6 months, how many times have you had group intercourse involving anal sex in which 
3... = 0Q21 Which of the following best describes your condom use during the group intercourse described in the 
previous question? 
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 I always used a condom  (1)  
 I sometimes used a condom  (2)  
 I never used a condom  (3) 
 
Q22 Which of the following best describes your position during the group intercourse described in the 
previous questions? 
 I always topped  (1)  
 I usually topped  (2)  
 I topped and bottom equally or almost equally  (3)  
 I usually bottomed  (4)  
 I always bottomed  (5)  
 
Q23 How many times had you been diagnosed with any form of a sexually transmitted disease (i.e. 
chlamydia, syphilis, gonorrhea) in the year before beginning PrEP? (If N/A, select 0) 
▼ 0 (1) ... 6+ (8) 
Q24 How many times have you been diagnosed with any form of a sexually transmitted disease since 
you began taking PrEP? (If N/A, select 0) 
▼ 0 (1) ... 6+ (7) 
 
 
 
 
 
 
 
 
 
 
 
 
34 
 
Q25 Please 
indicate how 
much you 
agree or 
disagree with 
the following 
statements: 
Strongly 
agree (11) Agree (12) 
Somewhat 
agree (13) 
Somewhat 
disagree (15) Disagree (16) 
Strongly 
disagree (17) 
Being on PrEP 
makes me 
feel more 
protected 
against HIV 
than if I were 
not on PrEP 
(1)  
o  o  o  o  o  o  
Being on PrEP 
makes me 
feel more 
protected 
against 
sexually 
transmitted 
infections 
(STIs) than if I 
were not on 
PrEP. (2)  
o  o  o  o  o  o  
Being in 
college is part 
of why I 
wanted to 
take PrEP. (3)  
o  o  o  o  o  o  
I feel safer 
having sex 
with new 
people 
knowing that 
they might 
also be taking 
PrEP. (4)  
o  o  o  o  o  o  
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I feel 
comfortable 
having sex 
with an HIV 
positive 
partner while 
I am on PrEP 
and using a 
condom. (5)  
o  o  o  o  o  o  
I feel 
comfortable 
having sex 
with an HIV 
positive 
partner while 
I am on PrEP 
and not using 
a condom. (6)  
o  o  o  o  o  o  
My overall 
sexual health 
has improved 
since 
beginning 
PrEP. (7)  
o  o  o  o  o  o  
I do not need 
to use 
condoms 
while I am on 
PrEP. (8)  
o  o  o  o  o  o  
My provider 
told me that I 
should use 
condoms 
while on 
PrEP. (9)  
o  o  o  o  o  o  
My provider 
told me 
about the 
risks of 
sexually 
transmitted 
infections 
while on 
PrEP. (10)  
o  o  o  o  o  o  
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I prefer to 
have sex 
without 
condoms, 
even if it 
increases my 
STI risk. (11)  
o  o  o  o  o  o  
 
 
End of Block: Participants Currently Taking PrEP 
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APPENDIX B: DATA COLLECTION INSTRUMENT 
(PARTICIPANTS INTERESTED IN INITIATING PREP) 
  
38 
 
Start of Block: Demographic Information 
 
Q5 What is your race? 
 American Indian or Alaskan Native  (1)  
 Asian of Pacific Islander  (2)  
 Black or African American  (3)  
 Multiracial  (4)  
 White  (5)  
 Other  (6)  
Display This Question: 
If What is your race? = Other 
Q55 Please specify race: 
________________________________________________________________ 
 
Q6 Are you Hispanic or Latino? 
 Yes  (1)  
 No  (2)  
 
Q7 What is your age? 
▼ 18 (8) ... 24 (14) 
 
Q8 Which of the following best describes your current gender? 
 Male (M)  (1)  
 Transgender (F to M)  (2)  
 Other  (3)  
Display This Question: 
If Which of the following best describes your current gender? = Other 
Q57 Please specify gender: 
________________________________________________________________ 
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Q9 Which of the following best describes your sexual orientation? 
 Gay  (1)  
 Bisexual  (2)  
 Pansexual  (3)  
 Other  (4)  
Display This Question: 
If Which of the following best describes your sexual orientation? = Other 
Q58 Please specify sexual orientation: 
________________________________________________________________ 
 
Q13 What is your current relationship status? 
 Single (Never Married)  (1)  
 Single (Divorced)  (2)  
 In a Relationship (Exclusive)  (3)  
 In a Relationship (Open Relationship or Open to Group Intercourse)  (4)  
 Married (Exclusive)  (5)  
 Married (Open Relationship or Open to Group Intercourse)  (6)  
 
Q14 Which of the following best describes your preferred anal sex position? 
 Strictly Top  (1)  
 Versatile Top  (2)  
 Versatile  (3)  
 Versatile Bottom  (4)  
 Strictly Bottom  (5)  
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Q10 What is your highest education received? 
▼ Current College Student (Undergraduate or Graduate Student) (1) ... Graduate Level Degree (10) 
Q12 Which of the following describes your current Pre-Exposure Prophylaxis (PrEP, or Truvada®) status? 
 I am currently taking daily PrEP.  (1)  
 I am not currently taking PrEP, but I may be interested in beginning PrEP treatment in the future.  
(2)  
 
End of Block: Demographic Information 
Start of Block: Participants Interested in Taking PrEP 
 
Q60  
Please rank your top reasons for considering PrEP (e.g. reason of interest for seeking PrEP prescription). 
Rank as many as apply, with the primary reason(s) placed at the top of the box in order of significance 
(top to bottom). If none apply, place all items in the N/A box. 
Select responses by dragging the options from the left to the appropriate box to the right. 
Please rank top (most impactful) to bottom (least 
impactful) N/A - This reason did not influence my decision. 
______ I want to have sex without worrying about HIV 
as much (1) 
______ I want to have sex without worrying about HIV 
as much (1) 
______ I want to take drugs using needles without 
worrying about HIV as much (2) 
______ I want to take drugs using needles without 
worrying about HIV as much (2) 
______ I want to use condoms less when having sex 
(3) 
______ I want to use condoms less when having sex 
(3) 
______ One or more of my sexual partners is HIV 
positive (4) 
______ One or more of my sexual partners is HIV 
positive (4) 
______ I want to have sex without worrying about 
transmitted infections as much (5) 
______ I want to have sex without worrying about 
transmitted infections as much (5) 
______ Other (Specify Below) (6) ______ Other (Specify Below) (6) 
 
Display This Question: 
If Please rank your top reasons fortaking PrEP (e.g. reason for seeking PrEP prescription). Rank as ma = Other 
(Specify Below) [ Please rank top (most impactful) to bottom (least impactful) ] 
Q61 Please specify other reason for taking PrEP: 
________________________________________________________________ 
41 
 
What is the primary reason(s) that you have not started taking PrEP yet? 
 The drug is too expensive and/or my insurance does not cover PrEP  (1)  
 I do not have a provider that I am able to obtain PrEP from  (2)  
 I do not want to (or cannot) visit my provider every 3 months for followup  (3)  
 I am worried about the side effects of the drug  (4)  
 I don't want to have to take a pill daily -or- I think I will forget to take a pill daily  (5)  
 Other  (6)  
Display This Question: 
If What is the primary reason(s) that you have not started taking PrEP yet? = Other 
Q62 Please specify other reason: 
________________________________________________________________ 
 
Q42 Which of the following best describes your current rate of condom use? 
 I always use condoms  (1)  
 I usually use condoms  (2)  
 I rarely use condoms  (3)  
 I never use condoms  (4)  
 
Q43 Which of the following do you think would best describe your condom use if you started taking 
PrEP? 
 I would use condoms much more frequently  (1)  
 I would use condoms somewhat more frequently  (2)  
 My condom use would not change  (3)  
 I would use condoms somewhat less frequently  (4)  
 I would use condoms much less frequently  (5)  
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Q63 How many male anal sex partners have you had in the past six months? 
▼ 0 (9) ... 26+ (7) 
 
Q64 In the past 6 months, how many times have you had group intercourse involving anal sex in which 
3 or more men participated (including yourself)? (If you have not had group intercourse, select 0) 
▼ 0 (1) ... 11+ (12) 
 
Skip To: Q65 If In the past 6 months, how many times have you had group intercourse involving anal sex in which 
3... = 0 
 
 
Q44 Which of the following best describes your condom use during the group intercourse described in 
the previous question? 
 I always used a condom  (1)  
 I sometimes used a condom  (2)  
 I never used a condom  (3)  
 
Q48 Which of the following best describes your position during the group intercourse described in the 
previous questions? 
 I always topped  (1)  
 I usually topped  (2)  
 I topped and bottomed equally or almost equally  (3)  
 I usually bottomed  (4)  
 I always bottomed  (5)  
 
Q65 How many times had you been diagnosed with any form of a sexually transmitted disease (i.e. 
chlamydia, syphilis, gonorrhea) in the past year? (If N/A, select 0) 
▼ 0 (1) ... 6+ (8) 
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Q51 Please 
indicate how 
much you 
agree or 
disagree with 
the following 
statements: 
Strongly 
agree (1) Agree (2) 
Somewhat 
agree (3) 
Somewhat 
disagree (4) Disagree (5) 
Strongly 
disagree (6) 
I will be more 
protected 
against HIV if 
I start taking 
PrEP. (1)  
o  o  o  o  o  o  
I will have sex 
with more 
people than I 
do now once 
I am taking 
PrEP. (2)  
o  o  o  o  o  o  
I will be more 
protected 
against 
sexually 
transmitted 
infections 
(STIs) if I start 
taking PrEP. 
(3)  
o  o  o  o  o  o  
Being in 
college is part 
of why I want 
to start 
taking PrEP. 
(4)  
o  o  o  o  o  o  
I feel safer 
having sex 
with new 
people 
knowing that 
they might be 
taking PrEP. 
(5)  
o  o  o  o  o  o  
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I would feel 
comfortable 
having sex 
with 
someone 
that is HIV 
positive if I 
were on PrEP 
and using a 
condom. (6)  
o  o  o  o  o  o  
I would feel 
comfortable 
having sex 
with 
someone 
that is HIV 
positive if I 
were on PrEP 
and not using 
a condom. (7)  
o  o  o  o  o  o  
My overall 
sexual health 
would 
improve if I 
began PrEP. 
(8)  
o  o  o  o  o  o  
I would not 
use condoms 
after starting 
PrEP. (9)  
o  o  o  o  o  o  
I prefer to 
have sex 
without 
condoms, 
even if it 
increases my 
STI risk. (10)  
o  o  o  o  o  o  
 
 
End of Block: Participants Interested in Taking PrEP 
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APPENDIX C: IRB APPROVAL 
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APPENDIX D: RECRUITMENT FLYER 
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APPENDIX E: DEMOGRAPHIC TABLE 
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Baseline Characteristic Participants 
Currently 
Taking PrEP  
Participants 
Expressing 
Interest in PrEP 
Full Sample 
n % n % n % 
Gender       
 Cisgender Male 5 83.3 24 77.4 29 78.4 
 Transgender Male 1 16.7 1 3.2 2 5.4 
 Undisclosed 0 0 6 19.4 6 16.2 
Race       
 White 2 33.3 12 38.7 14 37.8 
 Black or African 
American 
2 33.3 7 22.6 9 24.3 
 Asian or Pacific 
Islander 
1 16.7 1 3.2 2 5.4 
 American Indian or 
Alaskan Native 
0 0 1 3.2 1 2.7 
 Multiracial 1 16.7 3 9.7 4 10.8 
 Undisclosed 
Ethnicity 
0 0 7 22.6 7 18.9 
 Hispanic or Latino 3 50.0 9 29.0 12 32.4 
 Non-Hispanic or 
Latino 
3 50.0 16 51.6 19 51.4 
 Undisclosed 0 0 6 19.4 6 16.2 
Sexual Orientation       
 Gay 4 66.7 17 54.8 21 56.8 
 Bisexual 0 0 8 25.8 8 21.6 
 Pansexual 2 33.3 0 0 2 5.4 
 Undisclosed 0 0 6 19.4 6 16.2 
Relationship Status       
  Single (Never 
Married) 
5 83.3 14 45.2 19 51.4 
 Single (Divorced) 0 0 1 3.2 1 2.7 
  “Open” Relationship 0 0 3 9.7 3 8.1 
  “Closed” 
Relationship 
1 16.7 7 22.6 8 21.6 
  Undisclosed 0 0 6 19.4 6 16.2 
Preferred Sexual Position       
  Top (Insertive) 5 83.3 8 25.8 13 35.1 
  Bottom (Receptive) 1 16.7 7 22.6 8 21.6 
  Versatile 0 0 10 32.3 10 27.0 
  Undisclosed 0 0 6 19.4 6 16.2 
Highest Education        
  Current Student 3 50.0 18 58.1 21 56.8 
  Two-Year Degree 1 16.7 2 6.5 3 8.1 
  Four-Year Degree 1 16.7 3 9.7 4 10.8 
  Some Undergraduate  0 0 2 6.5 2 5.4 
  Undisclosed 1 16.7 6 19.4 7 18.9 
   Note: N = 37. The mean age of all participants was 21. 
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Participants Expressing Interest in Pre-Exposure Prophylaxis 
 Primary 
Motivator 
2nd Most 
Influential 
Motivator 
3rd Most 
Influential 
Motivator 
4th Most 
Influential 
Motivator 
5th Most 
Influential 
Motivator 
Being able to engage in 
sexual activity with 
reduced fear of HIV. 
11 8 1 0 0 
Being able to use 
condoms less when 
having sex. 
2 4 5 3 1 
Being able to engage in 
sexual activity with 
reduced fear of sexually 
transmitted infections. 
5 5 2 1 0 
Having one or more 
HIV positive sexual 
partner(s). 
2 1 3 1 0 
Increased protection 
from HIV with 
parenteral drug use. 
1 0 2 0 3 
 
 
Participants Currently Taking Pre-Exposure Prophylaxis 
 Primary 
Motivator 
2nd Most 
Influential 
Motivator 
3rd Most 
Influential 
Motivator 
4th Most 
Influential 
Motivator 
5th Most 
Influential 
Motivator 
Being able to engage in 
sexual activity with 
reduced fear of HIV. 
4 0 0 0 0 
Being able to use 
condoms less when 
having sex. 
0 3 1 0 0 
Being able to engage in 
sexual activity with 
reduced fear of sexually 
transmitted infections. 
0 1 2 0 0 
Having one or more 
HIV positive sexual 
partner(s). 
0 0 0 0 0 
Increased protection 
from HIV with 
parenteral drug use. 
0 0 0 0 0 
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